The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Solar stocks drop sharply as Senate Republicans detail changes to Trump’s tax-and-spending bill that would phase out solar, ...

Verve Therapeutics remains an early-stage biotech, making the rally purely acquisition-driven, not based on fundamentals.

Eli Lilly acquires Verve Therapeutics, Inc. for $1B to advance gene-editing therapies like VERVE-102, targeting ASCVD. Click ...

Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives ...

US Big Pharma firm Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion as the ...

Sunrun (RUN), Plug Power (PLUG), and Array Technologies (ARRY) plunge after the Senate revealed its revisions to President ...

Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising ...

Eli Lilly has announced that it will be acquiring Verve Therapeutics in a deal worth approximately $1.3bn, marking a ...

On the sidelines of BIO2025, Julie Gilmore, head of Lilly Gateway Labs, shares her thoughts on the $1.3 billion Verve Therapeutics buy, where Lilly’s therapeutic puck is potentially going and how the ...

With plenty of GLP-1 money to spend, Eli Lilly and Co. is buying Verve Therapeutics Inc. and its gene-editing program for ...